Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Everest Medicines Says Kidney Disease Therapy Effective in Asian Patients

publication date: Oct 5, 2023

Everest Medicine reported positive data for Asian patients in a Phase III study of NefIgArd, a treatment for IgA Nephropathy. Nefecon® was shown to lower circulating levels of IgA-IC IgA-containing immune complexes, which accumulate in renal tissue, triggering inflammation and scarring of the glomeruli. Nefecon® is a delayed release formulation of corticosteroid that is designed to remain intact until it reaches the lower small intestine. Everest expects a positive ruling on its China NDA for Nefecon later this year. In 2019, the company acquired greater China rights to the drug from Sweden’s Calliditas in a $121 million agreement. More details....

Stock Symbol: (HK: 1952)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here